Status:
COMPLETED
The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Roche Pharma AG
Fred Hutchinson Cancer Center
Conditions:
Bone Marrow Stem Cell Transplant
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being done in stem cell transplant recipients to see if taking the drug valganciclovir can prevent or reduce serious cytomegalovirus (CMV) infections that can occur 100 days or later aft...
Detailed Description
This study is a phase III, randomized, double-blind, palacebo-controlled, multicenter study of the drug valganciclovir. This study is to see if taking prophylactic doses of valganciclovir starting 100...
Eligibility Criteria
Inclusion
- Participants who are undergoing allogeneic peripheral blood stem cell, cord blood, or marrow transplantation that are 18 years of age or older, may be eligible to participate in this study.
Exclusion
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00275665
Start Date
November 1 2001
End Date
July 1 2007
Last Update
December 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905